Key facts
- This page summarizes David Bharucha's Form 4 filing for Milestone Pharmaceuticals Inc. (MIST).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 29 Jan 2025, 16:15.
David Bharucha - 27 Jan 2025 Form 4 Insider Report for Milestone Pharmaceuticals Inc. (MIST)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- MIST
- Reported as of
- 27 Jan 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 29 Jan 2025, 16:15:10 UTC
- Prior SEC filing
- 17 Feb 2023
- Next SEC filing
- 15 Jul 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jason Minio, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David Bharucha filed Form 4 for Milestone Pharmaceuticals Inc. (MIST) on 29 Jan 2025.
Change
- Previous filing in this sequence was filed on 17 Feb 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MIST
transaction
Derivative
Employee Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +120,600
- Change %
- Price
- $0.000000
- Shares after
- 120,600
- Date
- 27 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 120,600
- Exercise price
- $2.02
- Footnotes
- F1
MIST
transaction
Derivative
Restricted Stock Unit
Award
- Transaction value
- $0
- Shares
- +80,400
- Change %
- Price
- $0.000000
- Shares after
- 80,400
- Date
- 27 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 80,400
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
One-fourth (1/4th) of the shares subject to the option vest on Jaunary 27, 2026, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
Footnote F2
Each restricted stock unit represents a contingent right to receive one common share.
Footnote F3
One-fourth (1/4th) of the shares subject to the restricted stock unit award vest on each of Jaunary 27, 2026, Jaunary 27, 2027, Jaunary 27, 2028 and Jaunary 27, 2029, subject to the Reporting Person continuing to provide service through each such date.